http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S61204171-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_692dc75829481c48c017b52f352e2bad
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 1985-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfea4f032652a245e3c346be6846eb2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1fcde0422ce6e67f783060426bb338a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d924f2c203ae14776ca7d73b2cb3b647
publicationDate 1986-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-S61204171-A
titleOfInvention 5-fluorouracil derivative and medicinal drug preparation containing same
abstract NEW MATERIAL:The 5-fluorouracil derivative of formula (R is acyl derived from triene higher fatty acid or pentaene higher fatty acid). n EXAMPLE: 1-(α-Linoleylaminomethylcarbamoyl)-5-fluorouracil. n USE: A carcinostatic agent and platelet coagulation inhibitor. n PREPARATION: The objective compound of formula is produced by reacting 5-fluorouracil (5-FU) with the compound of formula R-NHCH 2 CO 2 H in a solvent such as dimethylformamide, dioxane, etc., in the presence of diphenylphos phorylazide. The compound exhibits an antitumor activity (carcinostatic activity) comparable to or higher than 5-FU, and has lower toxicity than 5-FU. It has strong platelet coagulation inhibiting activity which cannot be found in 5-FU. It is administered in a dose of preferably about 1W3g daily for adults. n COPYRIGHT: (C)1986,JPO&Japio
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE46608-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE46605-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9486534-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9238077-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9278136-B2
priorityDate 1985-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S5663966-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S5581865-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490115
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504969
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID236151374
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88690040
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31275
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419485438
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419530397
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414898412
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8004
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID199401
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6228

Total number of triples: 35.